Advances in health: Implications and challenges of intellectual property in the era of precision medicine
Why this work is in the frame
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Bibliographic record
Abstract
This study explores the role of intellectual property (IP) in developing and commercializing melanoma biomarkers within the pharmaceutical market, focusing on precision medicine (PM). It investigates five key areas: (i) inventiveness dynamics, (ii) commercial and epidemiological motivations for patent registrations, (iii) the impact of patented technologies, (iv) the classification of technological innovations, and (v) patterns of knowledge sharing and collaboration. This study analyzes 244 Patent families (FamPat) records from Questel’s Orbit database, selected without temporal restrictions up to 2023, ensuring a comprehensive longitudinal perspective. Employing a mixed-methods approach, the study combines quantitative trend analysis with qualitative content examination to classify innovations in melanoma biomarkers and assess intellectual property dynamics. Additionally, network analysis maps knowledge flows and collaboration patterns among patent assignees, offering an in-depth view of innovation trajectories and collaborative behaviors in this technological domain. The findings highlight two primary categories of melanoma biomarkers: those for predicting and monitoring disease progression and those that support therapeutic decision-making. Despite the U.S. leading patent filings since 1993, China, Europe, Canada, and Japan demonstrate more impactful innovations in this domain. Limited knowledge-sharing and collaboration between entities were observed, which may restrict further technological advancements in the market. This study offers novel insights into the convergence of IP and precision medicine in melanoma treatment. It reveals a paradigm shift towards bioinformatics-driven biomarkers and underscores the strategic importance of intellectual property for competitive positioning within the global pharmaceutical market. Findings support strategic decision-making for pharmaceutical firms involved in melanoma treatment, particularly concerning market expansion and intellectual property management.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it